CVAC

DGAP-News: CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Retrieved on: 
Monday, January 17, 2022 - 12:04pm

Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.

Key Points: 
  • Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.
  • "Mariola's dedication and expertise helped to build CureVac and fundamentally contributed to the advancement of mRNA technology as a whole."
  • "Mariola's groundbreaking work and innovations in mRNA technology have strongly contributed to CureVac becoming the world's pioneering company to harness mRNA for medical purposes," added Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
  • Mariola Fotin-Mleczek joined CureVac in May 2006 and became a member of the management board in 2013, first as Chief Scientific Officer and as Chief Technology Officer in 2018.

DGAP-News: dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.

Retrieved on: 
Thursday, January 13, 2022 - 10:08pm

DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG

Key Points: 
  • DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG
    dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
  • dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
    WALLDORF / BERLIN , Germany - 13 January 2022 - Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt fr Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (Nasdaq: CVAC).
  • In due course and solely to finance the restructuring (including tax obligations for involved parties), dievini intends to sell CureVac common shares.
  • Apart from this, dievini, Dietmar Hopp and his holding company, DH-LT-Investments, as well as the Federal Republic of Germany currently do not plan to sell CureVac common shares to third parties.

DGAP-News: CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Retrieved on: 
Monday, November 22, 2021 - 7:15pm

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Key Points: 
  • CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
    The issuer is solely responsible for the content of this announcement.
  • The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty(R) (Pfizer/BioNTech).
  • The data confirm how targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model, providing substantiated support for the unmodified mRNA technology approach.
  • This applies not only to the development of COVID-19 vaccines but to the mRNA technology field as a whole.

DGAP-News: CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

Retrieved on: 
Wednesday, November 10, 2021 - 12:12pm

Extensive analysis of immune cell activation shows efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma signaling pathways.

Key Points: 
  • Extensive analysis of immune cell activation shows efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma signaling pathways.
  • Serial tumor biopsies from individual patients demonstrated increased infiltration of tumor-fighting T cells in the microenvironment of injected as well as non-injected tumors.
  • The data are being presented at the Society for Immunotherapy of Cancer (SITC) Conference, held in Washington, D.C., and virtually from November 10-14, 2021.
  • "The preliminary data from the Phase 1 dose escalation part of this study allow a much deeper understanding of the promising biologic effects of CV8102 observed in several patients," said Dr. Klaus Edvardsen, Chief Development Officer at CureVac.

DGAP-News: CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

Retrieved on: 
Tuesday, October 12, 2021 - 12:19pm

Published pre-clinical results have shown the strong potential of the initial second-generation mRNA COVID-19 vaccine candidate, CV2CoV, compared to CureVac's first generation mRNA, CVnCoV.

Key Points: 
  • Published pre-clinical results have shown the strong potential of the initial second-generation mRNA COVID-19 vaccine candidate, CV2CoV, compared to CureVac's first generation mRNA, CVnCoV.
  • In parallel to the work on the second-generation mRNA vaccine technology, GSK and CureVac will accelerate efforts to progress the development of modified mRNA vaccine constructs.
  • To complement the development of this second generation non-modified mRNA technology, we have also initiated the development of modified mRNA technologies as part of our collaboration."
  • This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies.

Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots

Retrieved on: 
Friday, September 17, 2021 - 2:45pm

As well, as BioElpida is advancing preparations for GMP manufacturing of BVX-0918A, the preparation of the new manufacturing facility is ongoing and on schedule.

Key Points: 
  • As well, as BioElpida is advancing preparations for GMP manufacturing of BVX-0918A, the preparation of the new manufacturing facility is ongoing and on schedule.
  • "This major step is essentially a 'dry-run' for manufacturing the vaccine and preparation for GMP production,"said BioElpida President Gilles Devilliers.
  • Researchers behind the AstraZeneca PLC (AZN) candidate have designed a two-dose cancer vaccine using the same viral vector technology used in its Covid-19 treatment.
  • According to analysts , the mRNA cancer vaccine market is expected to boom to $127 billion at a CAGR of +28% between 2021-2028.

Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots

Retrieved on: 
Friday, September 17, 2021 - 2:45pm

VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- USA News Group  -  Using the same technology as their Covid-19 shot, scientists behind the University of Oxford and AstraZeneca PLC (NASDAQ:AZN) are getting closer to developing a therapeutic cancer vaccine, based on promising animal studies results. Based on the rapidly accelerating development of Covid-19 tech, expectations are rising in the field of oncology to keep pace, with a COTA survey reporting two-thirds (66%) of cancer patients and their close family members reporting disappointment or frustration with the progress of investigational cancer treatments. Thankfully, AstraZeneca isn't the only group in this fight, with several promising developments coming from other biotech firms, such as BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF), BioNTech SE (NASDAQ:BNTX), CureVac N.V. (NASDAQ:CVAC), and Moderna, Inc. (NASDAQ:MRNA).

Key Points: 
  • As well, as BioElpida is advancing preparations for GMP manufacturing of BVX-0918A, the preparation of the new manufacturing facility is ongoing and on schedule.
  • "This major step is essentially a 'dry-run' for manufacturing the vaccine and preparation for GMP production,"said BioElpida President Gilles Devilliers.
  • Researchers behind the AstraZeneca PLC (AZN) candidate have designed a two-dose cancer vaccine using the same viral vector technology used in its Covid-19 treatment.
  • According to analysts , the mRNA cancer vaccine market is expected to boom to $127 billion at a CAGR of +28% between 2021-2028.

DGAP-News: CureVac Streamlines European Network for mRNA Product Manufacturing

Retrieved on: 
Tuesday, September 14, 2021 - 1:15pm

As a result, the existing contracts with WACKER for the manufacturing of the mRNA drug substance of CVnCoV and Celonic for the manufacturing and formulation of the mRNA drug substance of CVnCoV will be terminated.

Key Points: 
  • As a result, the existing contracts with WACKER for the manufacturing of the mRNA drug substance of CVnCoV and Celonic for the manufacturing and formulation of the mRNA drug substance of CVnCoV will be terminated.
  • CureVac's existing agreements with Rentschler Biopharma and Novartis for mRNA production and formulation are unaffected by this adjustment and remain in place.
  • CureVac first announced the build-up of its broad external European manufacturing network in November 2020, next to the ongoing expansion of large in-house clinical and commercial manufacturing capacities.
  • Since then, several manufacturing agreements were made with highly experienced Contract Development and Manufacturing Organization partners for each of the key manufacturing steps for CVnCoV.

DGAP-News: CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet

Retrieved on: 
Tuesday, August 31, 2021 - 12:07pm

As previously announced, the data were based on 228 adjudicated COVID-19 cases, occurring at least two weeks after administration of the second dose.

Key Points: 
  • As previously announced, the data were based on 228 adjudicated COVID-19 cases, occurring at least two weeks after administration of the second dose.
  • CVnCoV demonstrated overall vaccine efficacy of 48% against COVID-19 disease of any severity, including single non-respiratory mild symptoms.
  • Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020, respectively.
  • A pivotal Phase 2b/3, the HERALD study, with a 12g dose of CVnCoV was initiated in December 2020.

DGAP-News: CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Retrieved on: 
Monday, August 30, 2021 - 12:07pm

TBINGEN, Germany/ BOSTON, USA - August 30, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the publication entitled "Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model" in the peer-reviewed Journal of Hepatology .

Key Points: 
  • TBINGEN, Germany/ BOSTON, USA - August 30, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the publication entitled "Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model" in the peer-reviewed Journal of Hepatology .
  • It provides the first preclinical data demonstrating the therapeutic applicability of mRNA-encoded HNF4A (hepatocyte nuclear factor 4 alpha) transcription factor in the treatment of liver fibrosis and cirrhosis.
  • Liver fibrosis is characterized by the formation of scar tissue in the liver, causing gradual impairment of liver function.
  • "The results of our study provide the first direct preclinical evidence that HNF4A mRNA therapeutics have the potential to treat liver fibrosis.